{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACTOS%2Fpioglitazone&page=7",
    "query": {
      "intervention": "ACTOS/pioglitazone",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 258,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACTOS%2Fpioglitazone&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACTOS%2Fpioglitazone&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T12:42:15.532Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00545233",
      "title": "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "peginterferon alfa-2a [Pegasys]",
          "type": "DRUG"
        },
        {
          "name": "ribavirin [Copegus]",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2008-01",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2012-05-07",
      "last_synced_at": "2026-10-17T12:42:15.532Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00545233"
    },
    {
      "nct_id": "NCT00240370",
      "title": "A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Muraglitazar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1159,
      "start_date": "2003-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-09-14",
      "last_synced_at": "2026-10-17T12:42:15.532Z",
      "location_count": 70,
      "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Mesa, Arizona + 67 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Columbiana",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Carlisle",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00240370"
    },
    {
      "nct_id": "NCT05040087",
      "title": "Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Intensification of diabetes medication based largely on HbA1c levels",
          "type": "OTHER"
        },
        {
          "name": "Intensification of diabetes medication based on glucose levels",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Foundation for Atlanta Veterans Education and Research, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 127,
      "start_date": "2021-09-01",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-17T12:42:15.532Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05040087"
    },
    {
      "nct_id": "NCT00951379",
      "title": "Pioglitazone for Oral Premalignant Lesions",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oral Leukoplakia"
      ],
      "interventions": [
        {
          "name": "Pioglitazone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2010-02",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2016-04-06",
      "last_synced_at": "2026-10-17T12:42:15.532Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Iowa City, Iowa • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00951379"
    },
    {
      "nct_id": "NCT01087567",
      "title": "INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Intensive insulin",
          "type": "DRUG"
        },
        {
          "name": "Routine Care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2010-07",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-10-17T12:42:15.532Z",
      "location_count": 1,
      "location_summary": "Athens, Ohio",
      "locations": [
        {
          "city": "Athens",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01087567"
    },
    {
      "nct_id": "NCT00676338",
      "title": "Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "exenatide once weekly",
          "type": "DRUG"
        },
        {
          "name": "metformin",
          "type": "DRUG"
        },
        {
          "name": "sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 820,
      "start_date": "2008-11",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2015-04-09",
      "last_synced_at": "2026-10-17T12:42:15.532Z",
      "location_count": 18,
      "location_summary": "Buena Park, California • Los Angeles, California • Valencia, California + 15 more",
      "locations": [
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Valencia",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00676338"
    },
    {
      "nct_id": "NCT02072096",
      "title": "A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Glimepiride",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Acarbose",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        },
        {
          "name": "Exenatide once weekly (QW)",
          "type": "DRUG"
        },
        {
          "name": "Exenatide twice daily (BID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2014-02",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2019-10-09",
      "last_synced_at": "2026-10-17T12:42:15.532Z",
      "location_count": 16,
      "location_summary": "Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02072096"
    },
    {
      "nct_id": "NCT02278562",
      "title": "Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ESRD"
      ],
      "interventions": [
        {
          "name": "anakinra",
          "type": "DRUG"
        },
        {
          "name": "actos",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2014-10-22",
      "completion_date": "2017-03-01",
      "has_results": true,
      "last_update_posted_date": "2025-02-06",
      "last_synced_at": "2026-10-17T12:42:15.532Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02278562"
    },
    {
      "nct_id": "NCT03492580",
      "title": "A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dipeptidyl Peptidase-4 (DPP-4) Inhibitors",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like Peptide-1 (GLP-1) Agonist",
          "type": "DRUG"
        },
        {
          "name": "Anti-hyperglycemic Agents (AHA)",
          "type": "DRUG"
        },
        {
          "name": "Thiazolidinediones (TZD)",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylureas (SU)",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 714582,
      "start_date": "2018-02-22",
      "completion_date": "2018-06-25",
      "has_results": false,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-10-17T12:42:15.532Z",
      "location_count": 1,
      "location_summary": "Titusville, New Jersey",
      "locations": [
        {
          "city": "Titusville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03492580"
    },
    {
      "nct_id": "NCT00121667",
      "title": "Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Saxagliptin + Metformin",
          "type": "DRUG"
        },
        {
          "name": "Placebo + Metformin",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 1462,
      "start_date": "2005-08",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2015-04-29",
      "last_synced_at": "2026-10-17T12:42:15.532Z",
      "location_count": 95,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 92 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Calera",
          "state": "Alabama"
        },
        {
          "city": "Haleyville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00121667"
    }
  ]
}